Webbläsaren som du använder stöds inte av denna webbplats. Alla versioner av Internet Explorer stöds inte längre, av oss eller Microsoft (läs mer här: * https://www.microsoft.com/en-us/microsoft-365/windows/end-of-ie-support).

Var god och använd en modern webbläsare för att ta del av denna webbplats, som t.ex. nyaste versioner av Edge, Chrome, Firefox eller Safari osv.

Cellular and behavioural effects of the adenosine A2a receptor antagonist KW-6002 in a rat model of l-DOPA-induced dyskinesia.

Författare

Summary, in English

We have examined the ability of KW-6002, an adenosine A2a antagonist, to modulate the dyskinetic effects of l-DOPA in 6-hydroxydopamine-lesioned rats. In animals rendered dyskinetic by a previous course of l-DOPA treatment, KW-6002 did not elicit any abnormal involuntary movements on its own, but failed to reduce the severity of dyskinesia when coadministered with l-DOPA. A second experiment was undertaken in order to study the effects of KW-6002 in l-DOPA-naive rats. Thirty-five animals were allotted to four groups to receive a 21-day treatment with: (i) KW-6002 (10 mg/kg/day); (ii) l-DOPA (6 mg/kg/day) i.p.; (iii) KW-6002 plus l-DOPA (same doses as above) or (iv) vehicle. Chronic treatment with KW-6002-only produced a significant relief of motor disability in the rotarod test in the absence of any abnormal involuntary movements. Combined treatment with l-DOPA and KW-6002 improved rotarod performance to a significantly higher degree than did each of the two drugs alone. However, this combined treatment induced dyskinesia to about the same degree as did l-DOPA alone. In situ hybridization histochemistry showed that KW-6002 treatment alone caused an approximately 20% reduction in the striatal levels of preproenkephalin mRNA, whereas neither the coadministration of KW-6002 and l-DOPA nor l-DOPA alone significantly altered the expression of this transcript in the dopamine-denervated striatum. Either alone or in combination with l-DOPA, KW-6002 did not have any modulatory effect on prodynorphin mRNA expression or FosB/ΔFosB-like immunoreactivity in the dopamine-denervated striatum.



These results show that monotreatment with an adenosine A2a receptor antagonist can relieve motor disability without inducing behavioural and cellular signs of dyskinesia in rats with 6-hydroxydopamine lesions. Cotreatment with KW-6002 and l-DOPA potentiates the therapeutic effect but not the dyskinesiogenic potential of the latter drug.

Publiceringsår

2003

Språk

Engelska

Sidor

1398-1410

Publikation/Tidskrift/Serie

Journal of Neurochemistry

Volym

84

Issue

6

Dokumenttyp

Artikel i tidskrift

Förlag

Wiley-Blackwell

Ämne

  • Neurosciences

Nyckelord

  • Parkinsonian Disorders: chemically induced
  • Oxidopamine
  • Levodopa: adverse effects
  • Motor Activity: drug effects
  • Female
  • Enkephalins: metabolism
  • Enkephalins: genetics
  • Disease Models
  • Animal
  • Behavior
  • Drug Therapy
  • Combination
  • Dyskinesia
  • Drug-Induced: complications
  • Drug-Induced: drug therapy
  • Corpus Striatum: metabolism
  • Corpus Striatum: drug effects
  • Animal: drug effects
  • Parkinsonian Disorders: complications
  • Parkinsonian Disorders: drug therapy
  • Protein Precursors: genetics
  • Protein Precursors: metabolism
  • Proto-Oncogene Proteins c-fos: metabolism
  • Purines: pharmacology
  • RNA
  • Messenger: metabolism
  • Rats
  • Sprague-Dawley
  • Receptors
  • Purinergic P1: antagonists & inhibitors
  • Treatment Outcome

Status

Published

Forskningsgrupp

  • Neurobiology
  • Neuronano Research Center (NRC)
  • Basal Ganglia Pathophysiology

ISBN/ISSN/Övrigt

  • ISSN: 1471-4159